Acadian Asset Management LLC Buys 34,321 Shares of Poseida Therapeutics, Inc. (NASDAQ:PSTX)

Acadian Asset Management LLC grew its stake in shares of Poseida Therapeutics, Inc. (NASDAQ:PSTX) by 9.4% during the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 399,839 shares of the company’s stock after buying an additional 34,321 shares during the quarter. Acadian Asset Management LLC owned approximately 0.41% of Poseida Therapeutics worth $1,165,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of PSTX. Dynamic Technology Lab Private Ltd bought a new stake in shares of Poseida Therapeutics during the fourth quarter worth $36,000. Cantor Fitzgerald L. P. bought a new stake in shares of Poseida Therapeutics during the fourth quarter worth $169,000. Russell Investments Group Ltd. acquired a new position in shares of Poseida Therapeutics during the first quarter worth $110,000. Blair William & Co. IL lifted its holdings in shares of Poseida Therapeutics by 41.3% during the first quarter. Blair William & Co. IL now owns 965,052 shares of the company’s stock worth $3,079,000 after purchasing an additional 282,310 shares during the period. Finally, Vanguard Group Inc. lifted its holdings in shares of Poseida Therapeutics by 16.3% during the first quarter. Vanguard Group Inc. now owns 3,373,065 shares of the company’s stock worth $10,760,000 after purchasing an additional 473,746 shares during the period. Institutional investors own 46.87% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of Poseida Therapeutics in a report on Tuesday, August 6th.

Poseida Therapeutics Price Performance

Shares of NASDAQ:PSTX opened at $3.07 on Monday. The firm has a market cap of $297.66 million, a PE ratio of -2.58 and a beta of 0.51. The company has a debt-to-equity ratio of 0.97, a quick ratio of 2.48 and a current ratio of 2.48. Poseida Therapeutics, Inc. has a 52 week low of $1.83 and a 52 week high of $4.27. The firm’s fifty day moving average is $3.09 and its 200-day moving average is $2.96.

Poseida Therapeutics (NASDAQ:PSTX) last released its earnings results on Monday, August 5th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.43) by $0.11. The business had revenue of $25.97 million for the quarter, compared to analyst estimates of $13.75 million. Poseida Therapeutics had a negative net margin of 127.48% and a negative return on equity of 121.01%. Sell-side analysts predict that Poseida Therapeutics, Inc. will post -1.57 earnings per share for the current year.

About Poseida Therapeutics

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.